RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CORALLO S
Collezione AOU Città della Salute di Torino

Items : 13

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. in The oncologist / Oncologist. 2022 Feb 3;27(1):e29-e36. doi: 10.1093/oncolo/oyab012.

2022
AOU Città della Salute di Torino

Fucà G; Raimondi A; Prisciandaro M; Lonardi S; Cremolini C; Ratti M; Clavarezza M; Murialdo R; Sartore-Bianchi A; Smiroldo V; Berenato R; Racca P; Bergamo F; Corallo S; Di Bartolomeo M; de Braud F; Morano F; Pietrantonio F;

Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. in British journal of cancer / Br J Cancer. 2022 Feb;126(3):449-455. doi: 10.1038/s41416-021-01591-8. Epub 2021 Nov 22.

2022
AOU Città della Salute di Torino

Ambrosini M; Prisciandaro M; Sottotetti E; Martinetti A; Randon G; Pagani F; Racca P; Murialdo R; Ratti M; Smiroldo V; Procaccio L; Antoniotti C; Corti F; Leone AG; Busico A; Fucà G; Lonardi S; Corallo S; Manca P; Raimondi A; Morano F; Pietrantonio F;

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. in ESMO open / ESMO Open. 2021 Oct;6(5):100246. doi: 10.1016/j.esmoop.2021.100246. Epub 2021 Aug 17.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Di Bartolomeo M; Pietrantonio F; Di Maio M; Morano F; Corallo S; Berenato R; Ratti M; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Ritorto G; Raimondi A; Fucà G; Leone AG; Lonardi S; Antoniotti C; Smiroldo V; Amatu A;

The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 May 1;27(9):2505-2514. doi: 10.1158/1078-0432.CCR-20-4699. Epub 2021 Feb 5.

2021
AOU Città della Salute di Torino

Prisciandaro M; Tamborini E; Perrone F; Palermo F; Martinetti A; Sottotetti E; Randon G; Pagani F; Racca P; Sartore-Bianchi A; Murialdo R; Tomasello G; Smiroldo V; Clavarezza M; Procaccio L; Antoniotti C; Corti F; Lonardi S; Busico A; Manca P; Corallo S; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F;

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

de Braud F; Di Bartolomeo M; Pietrantonio F; Randon G; Prisciandaro M; Ambrosini M; Pagani F; Niger M; Antista M; Longarini R; Cinieri S; Giordano M; Antonuzzo L; Petrelli F; Toscano G; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Racca P; Amatu A; Rimassa L; Antoniotti C; Morano F; Lonardi S; Corallo S; Raimondi A;

Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Morano F; Calareso G; Di Bartolomeo M; de Braud F; Vaiani M; Greco FG; Prisciandaro M; Pagani F; Palermo F; Raimondi A; Antista M; Clavarezza M; Racca P; Tomasello G; Murialdo R; Tampellini M; Zaniboni A; Smiroldo V; Antoniotti C; Bergamo F; Rimassa L; Lonardi S; Cremolini C; Randon G; Corallo S; Manca P;

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. in BMC cancer / BMC Cancer. 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.

2020
AOU Città della Salute di Torino

Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C;

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. in British journal of cancer / Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19.

2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tonini G; Adamo V; Loupakis F; Tomasello G; Zaniboni A; Murialdo R; Boccaccino A; Claravezza M; Bustreo S; Tampellini M; Borelli B; Sartore-Bianchi A; Rimassa L; Lonardi S; Marmorino F; Corallo S; Moretto R; Morano F; Antoniotti C; Guarini V; Fucà G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F; Fucà G; Guarini V; Antoniotti C; Morano F; et alii...

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.

2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Di Bartolomeo M; Peverelli G; de Braud F; Antista M; Niger M; Bergamo F; Cinieri S; Longarini R; Giordano M; Antonuzzo L; Petrelli F; Adamo V; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Ritorto G; Sartore-Bianchi A; Rimassa L; Antoniotti C; Corallo S; Lonardi S; Morano F; Raimondi A; Di Maio M; Raimondi A; Di Maio M; et alii...

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Longarini R; Petrelli F; Giordano M; Tomasello G; Adamo V; Zaniboni A; Murialdo R; Smiroldo V; Niger M; Antista M; Caporale M; Berenato R; Clavarezza M; Racca P; Tampellini M; Sartore-Bianchi A; Bergamo F; Rimassa L; Cremolini C; Raimondi A; Lonardi S; Miceli R; Corallo S; Pietrantonio F; Morano F; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; et alii...

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.

2019
AOU Città della Salute di Torino

Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F;

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. in BMC cancer / BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ciuffreda L; Basso M; Catalano V; Bracarda S; Verusio C; Maiello E; Cinieri S; Giuliani F; Tassinari D; Frassineti GL; Spallanzani A; Bonetti A; Tortora G; Scagliotti G; Pinotti G; Tomasello G; Bertolini A; Zaniboni A; Longarini R; Luporini AG; Rimassa L; Di Costanzo F; Cardellino GG; Scartozzi M; Berardi R; Di Donato S; Lonardi S; Tamberi S; Antista M; et alii...